Sarepta Therapeutics (SRPT) News Today $22.96 +1.07 (+4.87%) As of 02:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SRPT Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Tradr 2X Long SRPT Daily ETF2 hours ago | money.usnews.comTradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULFOctober 23 at 11:20 PM | msn.comSarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $18.00October 23 at 9:43 AM | marketbeat.comPrivium Fund Management B.V. Makes New $698,000 Investment in Sarepta Therapeutics, Inc. $SRPTOctober 21 at 6:04 AM | marketbeat.comBlair William & Co. IL Sells 16,942 Shares of Sarepta Therapeutics, Inc. $SRPTOctober 18, 2025 | marketbeat.comSarepta Therapeutics, Inc. $SRPT Shares Bought by Janney Montgomery Scott LLCOctober 18, 2025 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Trading Up 7% - Here's What HappenedOctober 17, 2025 | marketbeat.comWeiss Ratings Reiterates "Sell (D-)" Rating for Sarepta Therapeutics (NASDAQ:SRPT)October 16, 2025 | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Receives Sell (D-) Rating from Weiss RatingsOctober 14, 2025 | marketbeat.comAberdeen Group plc Boosts Stake in Sarepta Therapeutics, Inc. $SRPTOctober 14, 2025 | marketbeat.comInspire Investing LLC Raises Stake in Sarepta Therapeutics, Inc. $SRPTOctober 13, 2025 | marketbeat.comCautious Hold Rating on Sarepta Therapeutics Amid Promising but Inconclusive Sirolimus FindingsOctober 13, 2025 | tipranks.comSarepta Therapeutics: A Discounted Valuation Meets Breakthrough PipelineOctober 10, 2025 | seekingalpha.comSarepta Therapeutics (SRPT) Receives a Hold from Mizuho SecuritiesOctober 10, 2025 | theglobeandmail.comSarepta Therapeutics (SRPT) Receives a Buy from JefferiesOctober 10, 2025 | theglobeandmail.comWhat's Going On Sarepta Stock On Wednesday?October 8, 2025 | benzinga.comSarepta Therapeutics (NASDAQ:SRPT) Shares Gap Up After Analyst UpgradeOctober 8, 2025 | marketbeat.comRoyal Bank Of Canada Boosts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $16.00October 8, 2025 | marketbeat.comA Look at Sarepta Therapeutics (SRPT) Valuation Following Recent Share Price GainsOctober 6, 2025 | finance.yahoo.com25,360 Shares in Sarepta Therapeutics, Inc. $SRPT Bought by 111 CapitalOctober 6, 2025 | marketbeat.comSarepta (SRPT) on Soars 15.7% on 5th Day Ahead of Clinical Trial ResultsOctober 3, 2025 | insidermonkey.comSarepta: Q3 Earnings An Upcoming Catalyst, But Risks Undermine Any Contrarian PlayOctober 3, 2025 | seekingalpha.comSarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society CongressOctober 3, 2025 | businesswire.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of "Hold" from AnalystsOctober 3, 2025 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Trading Up 10.4% - What's Next?October 2, 2025 | marketbeat.comGenerali Investments CEE investicni spolecnost a.s. Grows Position in Sarepta Therapeutics, Inc. $SRPTOctober 1, 2025 | marketbeat.comSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 30, 2025 | businesswire.comTempus Wealth Planning LLC Has $353,000 Holdings in Sarepta Therapeutics, Inc. $SRPTSeptember 29, 2025 | marketbeat.comCantor Fitzgerald Keeps Their Hold Rating on Sarepta Therapeutics (SRPT)September 25, 2025 | theglobeandmail.comSarepta Therapeutics (SRPT) Receives a Hold from Evercore ISISeptember 25, 2025 | theglobeandmail.comKuehn Law Encourages Investors of Sarepta Therapeutics, Inc. to Contact Law FirmSeptember 24, 2025 | prnewswire.comAssenagon Asset Management S.A. Purchases 155,358 Shares of Sarepta Therapeutics, Inc. $SRPTSeptember 23, 2025 | marketbeat.comBMO upgrades Sarepta on Elevidys uptake, pipeline prospectsSeptember 22, 2025 | au.investing.comBMO Capital Upgrades Sarepta Therapeutics (SRPT)September 22, 2025 | msn.comSarepta Therapeutics (NASDAQ:SRPT) Rating Increased to Outperform at BMO Capital MarketsSeptember 22, 2025 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 5.2% - Still a Buy?September 17, 2025 | marketbeat.comUBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Raises Stock Position in Sarepta Therapeutics, Inc. $SRPTSeptember 17, 2025 | marketbeat.comSarepta Therapeutics' (SRPT) Buy Rating Reiterated at GuggenheimSeptember 16, 2025 | marketbeat.comInspire Investing LLC Buys New Holdings in Sarepta Therapeutics, Inc. $SRPTSeptember 15, 2025 | marketbeat.comQ3 EPS Forecast for Sarepta Therapeutics Raised by AnalystSeptember 13, 2025 | marketbeat.comLeerink Partnrs Issues Optimistic Forecast for SRPT EarningsSeptember 12, 2025 | marketbeat.comLeerink Partners Raises Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $15.00September 11, 2025 | marketbeat.com15,163 Shares in Sarepta Therapeutics, Inc. $SRPT Bought by Scientech Research LLCSeptember 10, 2025 | marketbeat.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Rating of "Hold" by AnalystsSeptember 9, 2025 | marketbeat.comEventide Asset Management LLC Lowers Position in Sarepta Therapeutics, Inc. $SRPTSeptember 6, 2025 | marketbeat.comSarepta Therapeutics, Inc. $SRPT Stock Holdings Lifted by EcoR1 Capital LLCSeptember 6, 2025 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Shares Up 6.1% - Still a Buy?September 5, 2025 | marketbeat.comSarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic YearSeptember 5, 2025 | businesswire.comSarepta Therapeutics, Inc. $SRPT Shares Purchased by 683 Capital Management LLCSeptember 4, 2025 | marketbeat.comADAR1 Capital Management LLC Acquires 82,919 Shares of Sarepta Therapeutics, Inc. $SRPTSeptember 4, 2025 | marketbeat.com Get Sarepta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SRPT Media Mentions By Week SRPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SRPT News Sentiment▼0.830.63▲Average Medical News Sentiment SRPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SRPT Articles This Week▼735▲SRPT Articles Average Week Get the Latest News and Ratings for SRPT and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Sarepta Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies CytomX Therapeutics News Today Editas Medicine News Today Rhythm Pharmaceuticals News Today Avidity Biosciences News Today Merus News Today Abivax News Today Cytokinetics News Today Nuvalent News Today CRISPR Therapeutics News Today Grifols News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SRPT) was last updated on 10/24/2025 by MarketBeat.com Staff From Our PartnersWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMy starkest warning in years Porter Stansberry — founder of one of the world’s largest financial research firms — believes we’re entering a...Porter & Company | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredIt’s Time to Buy “the NVIDIA of Quantum Computing”Yahoo Finance wrote that investing in quantum computing could... "Lead to life-changing returns... and make...Brownstone Research | SponsoredApple's secret partnerThe Tiny Company Apple Can’t Live Without A tiny company holds the key to Apple’s biggest breakthrough sinc...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SRPT Stock Alerts